Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin Treatment in Patients With Liver Cirrhosis: A Retrospective Cohort Study
Despite good tolerability, more than one-third of the patients experienced HE recurrence after rifaximin initiation. The aMAP risk score was useful for predicting the risk of recurrence, suggesting its potential clinical utility in the treatment of HE.
Authors
- Takashi Kosone
- Yuichi Yamazaki (ORCID: https://orcid.org/0000-0002-8633-2983)
- Hiroki Tojima (ORCID: https://orcid.org/0000-0002-1646-2344)
- H. Takagi
- Takeshi Hatanaka (ORCID: https://orcid.org/0000-0003-3656-285X)
- Atsushi Naganuma
- Satoshi Takakusagi (ORCID: https://orcid.org/0000-0002-4366-1699)
- Yozo Yokoyama
- Kyoko Marubashi
- Toshio Uraoka (ORCID: https://orcid.org/0000-0002-4425-4331)
- Kazuko Kizawa
- Satoru Kakizaki
Institutions
- Gunma University (JP)
- Fujitsu (Japan) (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/hepr.70110
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00